A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

NCT07365319 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

750

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer (Squamous or Non Squamous)
Stage 4 NSCLC

Interventions

DRUG: EIK1001
DRUG: Pembrolizumab (KEYTRUDA®)
DRUG: Placebo
DRUG: Paclitaxel + Carboplatin
DRUG: Nab-paclitaxel + Carboplatin
DRUG: Pemetrexed + Cisplatin /Carboplatin

Sponsor

Eikon Therapeutics

Collaborators

[object Object]